Genome Editing Market Growth, Opportunities and Forecast to 2028

Posted by Savni on November 11th, 2022

According to our new research study on “Genome Editing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End User,” the market is expected to grow from US$ 5.19 billion in 2021 to US$ 16.98 billion by 2028; it is estimated to grow at a CAGR of 18.4% during 2021–2028.  Factors driving the growth of the market are the rising prevalence of cancer, growing rate of genetic disorders, and rapidly growing research and development initiatives around gene editing tools and techniques. 

Download PDF Sample Copy at:

Impact of COVID-19 Pandemic on Genome Editing Market

The COVID-19 outbreak pandemic has marked the highest number of positive patients. Across the world, various healthcare research centers were working only for research on COVID-19 therapeutics. As the crisis moved forward, healthcare professionals realized that developing novel therapies using innovative technologies is essential to mitigate this unprecedented crisis. The lack of definitive therapy offers significant opportunities for the genome editing-related market as US FDA has recently approved the use of plasma therapy for critically ill COVID-19 patients. Upcoming stem cell therapies to boost patients’ immune systems and eliminate the virus would offer significant growth prospects for the market. The pandemic has positively impacted the genome editing market.

Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Horizon Discovery Group plc., Integrated DNA Technologies, GenScript, New England Biolabs, Eurofins Scientific, CRISPR Therapeutics, and Editas Medicine are among the leading companies operating in the genome editing market.

Company Overview:

Company overview provides the information about location of the company where it is headquartered along with the established year, employee strength as of 2017, regions where the company is operating and the key business areas.

Financial Performance:

Overall company/segment revenue for the year 2019, 2018, and 2017 is provided in the sub title “Financial Performance” (public listed companies) along with the analysis and explanation of the increase or decrease in the same due to factors such as mergers & acquisition, profit or loss in any strategic business unit (SBUs) and others.

Product Benchmarking:

Product benchmarking comprises the comprehensive list of products pertaining to the respective market along with the application and key features.

Strategic Initiatives:

Insights pertaining to the new product launch, strategic collaboration, mergers and acquisition, regulatory approval, and other developments by the company in market are covered under strategic initiatives section.

We are keen to understand what additional information if included will help you in your business endeavor. We also hold the expertise to customize the reports based on any specific countries/regions, segmentations, companies, etc. of your choice. Hence you can share your specific requirements, if any. 

About The Insight Partners:

The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.

We offer our clients multiple ways to customize research as per their specific needs and budget.

Contact us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi


Phone: +1-646-491-9876 

Like it? Share it!


About the Author

Joined: October 21st, 2019
Articles Posted: 480

More by this author